Active surveillance for low-risk prostate cancer

被引：32

作者：

Bangma, Chris H. ^{[1
]}

Bul, Meelan ^{[1
]}

van der Kwast, Theo H. ^{[3
]}

Pickles, Tom ^{[5
]}

Korfage, Ida J. ^{[2
]}

Hoeks, Caroline M. ^{[6
]}

Steyerberg, Ewout W. ^{[2
]}

Jenster, Guido ^{[1
]}

Kattan, Michael W. ^{[7
]}

Bellardita, Lara ^{[4
]}

Carroll, Peter R. ^{[8
]}

Denis, Louis J. ^{[9
]}

Parker, Chris ^{[10
]}

Roobol, Monique J. ^{[1
]}

Emberton, Mark ^{[11
]}

Klotz, Laurence H. ^{[12
]}

Rannikko, Antti ^{[13
,14
]}

Kakehi, Yoshiyuki ^{[15
]}

Lane, Janet A. ^{[16
]}

Schroder, Fritz H. ^{[1
]}

Semjonow, Axel ^{[17
]}

Trock, Bruce J. ^{[18
]}

Valdagni, Riccardo ^{[4
]}

机构：

[1] Erasmus MC, Dept Urol, Rotterdam, Netherlands

[2] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands

[3] Mt Sinai Hosp, Univ Hlth Network, Dept Surg Pathol, Toronto, ON M5G 1X5, Canada

[4] Fdn IRCSS, Inst Nazl Tumori, Sci Directorate, Prostate Program, Milan, Italy

[5] British Columbia Canc Agcy, Dept Radiat Oncol, Vancouver, BC V5Z 4E6, Canada

[6] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6525 ED Nijmegen, Netherlands

[7] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA

[8] Univ Calif San Francisco, Dept Urol, San Francisco Med Ctr, San Francisco, CA 94143 USA

[9] Europa Uoma Secrtariat, Oncol Ctr Antwerp, Antwerp, Belgium

[10] Royal Marsden Natl Hlth Serv Fdn Trust, Acad Urol Unit, Sutton, Surrey, England

[11] Univ Coll Hosp, Div Surg & Intervent Sci, London, England

[12] Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON M4N 3M5, Canada

[13] Univ Helsinki, Cent Hosp, Dept Urol, Helsinki, Finland

[14] Univ Helsinki, Helsinki, Finland

[15] Kagawa Univ, Dept Urol, Fac Med, Takamatsu, Kagawa 760, Japan

[16] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England

[17] Univ Clin Munster, Dept Urol, Prostate Ctr, Munster, Germany

[18] Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2013年 / 85卷 / 03期

关键词：

Active surveillance; Prostate cancer; Screening; Overdiagnosis; Nomograms; Biomarkers; Imaging; TUMOR VOLUME; RADICAL PROSTATECTOMY; ANTIGEN; 3; MEN; MANAGEMENT; OUTCOMES; INTERVENTION; OVERDIAGNOSIS; VALIDATION; GUIDELINES;

D O I：

10.1016/j.critrevonc.2012.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients' perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference "Active Surveillance for low risk prostate cancer" (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers. (c) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：295 / 302

页数：8

共 65 条

[31] Intermixed Normal Tissue within Prostate Cancer: Effect on MR Imaging Measurements of Apparent Diffusion Coefficient and T2-Sparse versus Dense Cancers [J].